Sepracor Inc announced that positive data from three phase-III studies presented at the 8th European Congress of Epileptology in Berlin, demonstrated that eslicarbazepine acetate, a novel once-daily anti-epileptic agent, significantly reduced the frequency of partial seizures in patients with refractory partial epilepsy, in combination with other anti-epileptic agents.
The details can be read here.
No comments:
Post a Comment